Next, we examined the therapeutic potential of targeting the cell cycle regulator PLK1 that was identified both by differential expression analysis and multivariate partial-least squares regression as a predictor of poor lapatinib response in fibroblast-protected cancer cells. The gene discussed is PLK1; the disease is cancer.